TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) develops targeted therapies for cancer, wet AMD and fibrotic diseases. The company’s current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. For more information, visit the company’s website at www.traconpharma.com